ClinicalTrials.gg
RecruitingNCT07336134Updated Nov 16, 2026

PopSci CHW4CervixHealth

An interventional study of Evalyn® Brush and Copan Floqswab in Cervical Cancer, Hpv and Human Papilloma Virus, sponsored by Thomas Jefferson University. Recruiting at 1 site in United States. Open to female participants aged 25 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Thomas Jefferson University · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.
Updated Nov 16, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
25 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 834 studies in Uterine Cervical Neoplasms with a site in United States — 143 open to participants now, 218 under way, 6 of them phase 3. Uterine Cervical Neoplasms · United States.

Planned enrollment
256th of 678
120 · median 71
Started
2025
with 46 others
No phase
246 of 834
51 open now
Primary completion
2026-12
later than 51 of 217 live
Registered
807th of 834
by date

Among the 834 studies in Uterine Cervical Neoplasms with a site in United States, this one is the 256th largest by planned enrollment of the 678 interventional ones that give a count, is one of 47 that started in 2025, is one of 246 with no phase, reaches primary completion later than 51 of the 217 other live ones, and was the 807th registered.

Uterine Cervical Neoplasms

2,369 studies on the registry are indexed under Uterine Cervical Neoplasms; 678 are open to participants now.

Browse Uterine Cervical Neoplasms studies →

Open to participants now

143 of the 834 studies in Uterine Cervical Neoplasms with a site in United States are open now. Recruiting first, the newest first:

138 more — sign in →

All 143 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 476 Uterine Cervical Neoplasms studies recruiting now, 245 (51%) set no upper age limit and 191 (40%) stop at 75 or younger; 20 take children under 18; 68 take healthy volunteers.

This study: 25 Years to 65 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 834 studies in Uterine Cervical Neoplasms with a site in United States, or all of them as a file.
02

Study summary

Phase I: Validating self-collection kit by comparing their results with clinical Pap smear results in a cohort of 20 patients.

Phase II: Evaluate the feasibility and acceptability of the CHW4CervicalHealth: Use of a self-collection kit to improve cervical health screening intervention aimed to promote HPV self-collection uptake among screening-eligible and under-screened ethnic minority women in the community.

Read the detailed description

The self-collection kits will be collected at the clinic (Phase I) or at the end of the workshop (Phase II). A chain-of-custody form for each kit will be associated with the specimen and the clinic nurse will label and prepare to transport them via courier to the Jefferson NJ Molecular Virology lab, Cherry Hill, NJ; Richard Sunday, Lab Supervisor, will process according to Roche, the self-collected vaginal specimens suspended in PreservCyt® may be stored at 2-30°C (35.6- 86°F) for up to 1 month after the date of collection.

Phase I: In person accrual, enrollment and study implementation will take 15-30 minutes.

-Clinic staff will collect self-collection kit at appointment.

Phase II: Workshops will take about 30 minutes to complete and another 30 minutes to complete survey and self-collection kit use.

  • Conduct educational workshops in participants primary language
  • For those choosing to use the self-sample kit, obtain and document e-consent or paper consent from potential participants in their primary language.
  • Provide participants with self-collection testing kits during workshop along with instructions
  • Collect self-collection kit samples from participants and place in pre-made sample bags with appropriate label. CHW will take custody and coordinate with OBGYN clinic staff to drop off self-collected samples
  • Collect post workshop survey and conduct post workshop interviews or focus group
  • OBGYN staff set-up courier to send samples to NJ lab
03

Conditions studied

  • Cervical Cancer
  • Hpv
  • Human Papilloma Virus
  • HPV Infection

Keywords

  • Copan FLOQswab
  • Evalyn® Brush
  • HPV self-collection
  • self-collection
  • community health workers
  • underscreened women
  • concordance
04

Who can participate

Ages eligible
25 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Phase I:

  • Women aged 25-65 years
  • Scheduled for a Pap smear test appointment at Jefferson OBGYN Center City location
  • Willing and able to provide for participation in the study
  • Agree to perform an HPV self-collection collection procedure during the same visit
  • Have not undergone a hysterectomy (intact cervix required)

Phase II:

This intervention targets under-screened minority individuals who must meet all the following inclusion criteria to be eligible to participate in the study:

  • Women aged 25-65 years
  • Who has not had a Pap smear in the past three to five years based on age of prior screening and type of screening. If under the age of 30, in the past 3 years and if over the age of 30, in the past 5 years. Participant will self-report normal pap smear and date.
  • Self-identify as Hispanic, Black/African or Black Caribbean, Chinese, Korean, or Vietnamese
  • Competent to give consent and provide signed and dated informed consent form in their preferred language.

Exclusion criteria

Exclusion Criteria:

Phase I:

  • Current pregnancy (self-reported or confirmed)
  • Previous participation in an HPV self-collection study within the past 12 months
  • Presence of visible vaginal or cervical infection or symptoms suggestive of a current genital tract infection
  • Inability to comply with study procedures or follow instructions (e.g., due to language barriers or cognitive impairments)

Phase II:

An individual who meets any of the following criteria will be excluded from participation in this study:

  • Have a history of hysterectomy, cervical cancer
  • Self-report participation in a cervical cancer screening or other prevention study
  • Pregnant (self-reported)
  • Inability to provide
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Arm 1: Evalyn Brush Self-Collection - Phase I (Validation)

    Participants will be provided the Evalyn Brush self-sample kit at their scheduled Pap smear; a self-collected HPV test will also be collected as part of validation purposes for the study. Results will be shared from both their regularly scheduled appointment and the HPV self sample kit.

    Device: Evalyn® Brush

  • Experimental
    Arm 2: Evalyn Brush Self-Collection - Phase II (Community Implementation)

    Participants will be assigned to use the Evalyn Brush device to evaluate feasibility and acceptability of use. Trained bilingual community health workers (CHWs) will provide culturally-tailored community workshops about cervical health and cervical cancer prevention, distribution and collection of HPV self-collection, and follow-up from results when appropriate.

    Device: Evalyn® Brush · Behavioral: CHW4CervicalHealth

  • Experimental
    Arm 3: Copan FLOQSwab Self-Collection - Phase II (Community Implementation)

    Participants will be assigned to use the Copan FLOQSwab device to evaluate feasibility and acceptability of use. Trained bilingual community health workers (CHWs) will provide culturally-tailored community workshops about cervical health and cervical cancer prevention, distribution and collection of HPV self-collection, and follow-up from results when appropriate.

    Device: Copan Floqswab · Behavioral: CHW4CervicalHealth

Interventions

  • DeviceEvalyn® Brush

    Participants use Evalyn® Brush device to collect a cervical sample for HPV testing.

    Also known as: Rovers® Self-Sampling Device, simply Evalyn, Viba-Brush®

  • DeviceCopan Floqswab

    Participants use the Copan Floqswab device to collect a cervical sample for HPV testing.

    Also known as: 4N6FLOQSwabs® Genetics, eSwab®, hDNA Free FLOQSwabs®, flocked swabs, nylon-tipped swabs

  • BehavioralCHW4CervicalHealth

    The CHW4CervicalHealth intervention is a community health care worker (CHW)-led education and support program designed to promote HPV self-collection among underserved women. Trained bilingual CHWs provide culturally-tailored community workshops about cervical health and cervical cancer prevention, distribution and collection of HPV self-collection, and follow-up from results when appropriate.

06

What researchers measure

Primary outcomes

  1. Diagnostic Concordance of Self-Collected vs. Clinically collected sample (Phase I)

    Concordance rate between self-collection kit results and clinical Pap smear findings (measured as agreement in detection of HPV and/or abnormal cytology). Agreement between the two methods will be evaluated using Cohen's kappa statistic, with values interpreted based on standard benchmarks for strength of agreement. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value (NPV) will be calculated to determine the accuracy of self-collection kits relative to the clinician-collected gold standard.

    Time frame: at the visit (approximately 30 minutes) and analysis completed within 2 weeks

  2. Feasibility of HPV Self-Collection: Completion of Self-Collection Kit

    Feasibility will be assessed as the number of participants who proceed with HPV self-collection using the study kit out of the total number of participants enrolled in the study.

    Time frame: Within 12 months

Secondary outcomes

  1. Change in Participants' HPV-related knowledge and perceived comfort with self-collection

    Paired sample t-tests will analyze changes in knowledge scores from baseline to post-intervention. Statistical analysis will be conducted using SPSS 25, with significance set at p \< .05.

    Time frame: From Baseline to Post-Intervention (approximately 18 months)

07

Study locations

1 of 1 sites recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Dec 2026, 13 months after the start.

Of 446 non-industry interventional studies with no phase under Uterine Cervical Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 71. This study's planned 13 months is below that.

Counting every sponsor, half of 462 studies reached it within 33 months; a quarter within 15 and three quarters within 71.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: primary completion Oct 2026 → Dec 2026 and completion Oct 2026 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 7, 2025
First posted
Jan 13, 2026
StartActual
Oct 22, 2025
Primary completionEst.
Dec 1, 2026was Oct 2026
CompletionEst.
Dec 1, 2026was Oct 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Oct 1, 2026→Dec 1, 2026
Nov 16, 2026
Study completion
Oct 1, 2026→Dec 1, 2026
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Primary completion Oct 1, 2026→Dec 1, 2026
    Study completion Oct 1, 2026→Dec 1, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07336134
Collaborators
Roche Pharma AG
Responsible party
Sponsor
First posted
Jan 13, 2026
Start date
Oct 22, 2025
Primary completion
Dec 1, 2026 (estimated)
Completion
Dec 1, 2026 (estimated)
Last update
Nov 16, 2026

Study contacts

Site Public Contact
Contact
ONCTrialNow@jefferson.edu
215-600-9151
Sandra Dayaratna, MD, MBA
principal investigator · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University

Oversight

FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion